Investment Banking
An increase in M&A and financing activity to end biopharma's Q2 have rekindled hope that we’re finally out of the biotech winter, while others fear it’s just a false spring. As companies continue to weather the storm, the focus remains on cash runway, quality news flow/clinical data, and consolidation. William Blair's Biopharma team shares perspectives in The Quarterly Rx: Q2 2022 U.S. Biopharma Recap.
Complete the form below to download your copy of the report
Stay up-to-date with the latest William Blair news and insights
William Blair initiated research coverage of Inari Medical, Inc. (NARI $54.73), a medical device company that develops interventional products for patients suffering from venous diseases.
Read moreThis charitable vehicle provides a simplified approach that allows you to maximize your charitable donations and tax benefits—an approach that can transform the way you give.
Read moreWilliam Blair acted as the exclusive financial advisor to Clio in connection with its $900 million Series F investment round led by New Enterprise Associates, at a $3.0 billion valuation.
Read moreInformation contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures
